BRAF and metastatic melanoma: A 2021 meta-analysis supported the findings of this Cochrane review, concluding improved overall survival (hazard ratio [HR] 0.59, 95% CI 0.47-0.74) and progression-free survival (HR 0.24, 95% CI 0.19-0.3) when comparing BRAF + MEK inhibitors against conventional chemotherapy for unresectable metastatic melanoma (TNM [tumor, node, metastasis] stage IIIc) [3].